ArticleMolecular cancer therapeutics2024

MIG6 Mediates Adaptive and Acquired Resistance to ALK/ROS1 Fusion Kinase Inhibition through EGFR Bypass Signaling.

Nan Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.